Conference Track

Update on the Management of HCV and the Complications of Liver Disease

Source: CCO Independent Conference Coverage of the 2009 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Boceprevir Added to Standard of Care Results in High Response Rates in Treatment-Naive Patients With Genotype 1 HCV
High Dose-Ursodeoxycholic Acid Effective at Normalizing Serum ALT Levels in Patients With Nonalcoholic Steatohepatitis
Rapid HCV RNA Decline in Treatment-Naive Genotype 1 Patients With ITMN-191 Combined With Peginterferon alfa-2a Plus Ribavirin
SCH 900518 Potent and Well-Tolerated in Patients Infected With Genotype 1 HCV
Nonnucleoside HCV Polymerase Inhibitor VCH-916 Safe and Active in Treatment-Naive Patients Infected With Genotype 1 HCV
Rifaximin Protects Against Hepatic Encephalopathy Breakthrough
Larger Hemoglobin Decline During Peginterferon alfa Plus Ribavirin Therapy Associated With Higher Likelihood of Virologic Response in Treatment-Naive Genotype 1 HCV Patients
SUCCESS: 72-Week Duration of Peginterferon alfa-2b/Weight-Based Ribavirin Does Not Significantly Improve SVR Rates in Genotype 1 HCV Slow Responders vs 48 Weeks of Therapy
Albinterferon alfa-2b Noninferior to Peginterferon alfa-2a With Respect to SVR Rates in Genotype 1 HCV Patients
SVR Improved Upon Telaprevir Addition to Peginterferon alfa-2a Plus Ribavirin Therapy in Genotype 1 HCV Previous Nonresponders
Immediate Treatment of Acute HCV More Effective Than Delayed Treatment in Overall Population, Similar in Adherent Patients

Expert Analysis

Update on the Management of HCV and the Complications of Liver Disease

Faculty:

Adrian M. Di Bisceglie, MD, FACP
Michael P. Manns, MD
Stefan Zeuzem, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite new findings on the safety and efficacy of investigational antiviral agents including protease inhibitors and nonnucleoside polymerase inhibitors in patients with chronic HCV infection
Recount the latest results on the optimal treatment duration for HCV-infected patients who experience a slow response to peginterferon/ribavirin therapy
Discuss the relationship between on-treatment hemoglobin decreases, erythropoietin use, and virologic response among patients with chronic HCV infection
Summarize the results of recent clinical trials evaluating new approaches to treating and managing complications associated with advanced liver disease such as hepatic encephalopathy
Articulate the latest findings on the optimal timing of treatment for patients with acute hepatitis C infection

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: June 16, 2009

Expiration Date: June 15, 2010

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.